Publications (ENG)

All publications related to the CUREiHUS study are listed here:

Safety and effectiviness of restrictive eculizumab regimen in patients with aHUS

Twenty aHUS patients are described who received eculizumab for a short period of time after which therapy is withdrawn. This study shows a restrictive treatment regimen is feasable. Moreover, appears even safe and (cost)effective.

Eculizumab dosing regimen in atypical HUS: Possibilities for individualized treatment.

This study provides essential insight in optimization of eculizumab dosing schemes and lessening of therapy burden for the patients and cost of the treatment.

Development and Pretesting of a Questionnaire to Assess Patient Experiences and Satisfaction with Medications (PESaM Questionnaire).

The PESaM Questionnaire is an add-on study of the CUREiHUS study to assess patient experience and satisfaction with eculizumab.

Fecal diagnostics in combination with serology: Best test to establish STEC-HUS

The serological anti-O157 LPS assay clearly makes a positive contribution when used in combination with standard fecal diagnostic tests to diagnose STEC-HUS and should be incorporated in clinical practice.